ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.739,76
0,38%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Immatics NV (IMTX)

  7. Immatics NV (IMTX) News

IMTX

Immatics NV (IMTX)

Immatics NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IMTX
DatumZeitQuelleÜberschriftSymbolFirma
14/05/202413h00GlobeNewswire Inc.Immatics Announces First Quarter 2024 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
21/03/202412h00GlobeNewswire Inc.Immatics Announces Full Year 2023 Financial Results and Corporate UpdateNASDAQ:IMTXImmatics NV
22/01/202418h52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
19/01/202414h58Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMTXImmatics NV
18/01/202402h30GlobeNewswire Inc.Immatics Announces Pricing of $175 Million Public OfferingNASDAQ:IMTXImmatics NV
17/01/202422h11Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMTXImmatics NV
17/01/202422h01GlobeNewswire Inc.Immatics Announces Proposed Public OfferingNASDAQ:IMTXImmatics NV
16/01/202410h06PR Newswire (US)DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed FinancingNASDAQ:IMTXImmatics NV
16/01/202409h59PR Newswire (US)DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed FinancingNASDAQ:IMTXImmatics NV
30/11/202310h00GlobeNewswire Inc.Levicept Appoints Eliot Forster as CEONASDAQ:IMTXImmatics NV
14/11/202313h00GlobeNewswire Inc.Immatics Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
08/11/202313h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
08/11/202313h00GlobeNewswire Inc.Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 TrialNASDAQ:IMTXImmatics NV
24/10/202313h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
24/10/202313h00GlobeNewswire Inc.Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T MonotherapyNASDAQ:IMTXImmatics NV
14/09/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMTXImmatics NV
13/09/202323h03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:IMTXImmatics NV
11/09/202313h00GlobeNewswire Inc.Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsNASDAQ:IMTXImmatics NV
11/09/202312h33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
25/08/202322h11Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:IMTXImmatics NV
17/08/202313h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
17/08/202313h00GlobeNewswire Inc.Immatics Announces Second Quarter 2023 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
10/08/202313h08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
10/08/202313h00GlobeNewswire Inc.Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid TumorsNASDAQ:IMTXImmatics NV
24/07/202313h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMTXImmatics NV
24/07/202313h00GlobeNewswire Inc.Immatics Announces $35 Million Equity Investment from Bristol Myers SquibbNASDAQ:IMTXImmatics NV
20/06/202322h21Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMTXImmatics NV
16/05/202313h06Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMTXImmatics NV
16/05/202313h00GlobeNewswire Inc.Immatics Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:IMTXImmatics NV
02/05/202313h00GlobeNewswire Inc.Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAMENASDAQ:IMTXImmatics NV
 Showing the most relevant articles for your search:NASDAQ:IMTX

Kürzlich von Ihnen besucht

LSE
54HN
Irish Life
ASX
GSBQ26
Commonwealth of Australia
XE
B4NZ
BNP Paribas Arbitrage Is...
LSE
0Q15
Abbott Laboratories
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten